Prosecution Insights
Last updated: April 19, 2026

Acceleron Pharma, Inc.

7 pending office actions

Portfolio Summary

7
Total Pending OAs
3
Final Rejections
4
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18035329 FORMULATIONS COMPRISING ACTRII POLYPEPTIDE VARIANTS FISCHER, JOSEPH 1658 Non-Final OA May 04, 2023
18011261 ACTRII PROTEINS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) MIKNIS, ZACHARY J 1658 Final Rejection Dec 19, 2022
18010888 ACTRII-ALK4 ANTAGONISTS AND METHODS OF TREATING HEART FAILURE HOWARD, ZACHARY C 1674 Non-Final OA Dec 16, 2022
17797238 VARIANT ACTRIIB PROTEINS AND USES THEREOF HIBBERT, CATHERINE S 1658 Non-Final OA Aug 03, 2022
17784029 SINGLE-ARM ACTRIIA AND ACTRIIB HETEROMULTIMERS AND METHODS FOR TREATING PULMONARY HYPERTENSION HELLMAN, KRISTINA M 1654 Non-Final OA Jun 09, 2022
17289420 TREATMENT OF ANEMIA DUE TO VERY LOW, LOW, OR INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES IN SUBJECTS WITH RING SIDEROBLASTS USING ACTIVIN-ACTRll LIGAND TRAPS DEBERRY, REGINA M 1647 Final Rejection Apr 28, 2021
16987756 METHODS AND COMPOSITIONS FOR TREATING INEFFECTIVE ERYTHROPOIESIS MIKNIS, ZACHARY J 1658 Final Rejection Aug 07, 2020

Managing Acceleron Pharma, Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month